# AZD8186 First Time In Patient Ascending Dose Study

> **NCT01884285** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 147 (actual)

## Conditions studied

- Advanced Castrate-resistant Prostate Cancer CRPC
- Squamous Non-Small Cell Lung Cancer sqNSCLC
- Triple Negative Breast Cancer TNBC

## Interventions

- **DRUG:** Part A: AZD8186 monotherapy
- **DRUG:** Part B: AZD8186 monotherapy
- **DRUG:** Part C1: Abiraterone acetate combination with AZD8186
- **DRUG:** Part D1: AZD2014 combination with AZD8186
- **DRUG:** Part D2 AZD2014 combination with AZD8186
- **DRUG:** Part C2: Abiraterone acetate combination with AZD8186

## Key facts

- **NCT ID:** NCT01884285
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-09
- **Primary completion:** 2019-03-31
- **Final completion:** 2020-02-07
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2020-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01884285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01884285, "AZD8186 First Time In Patient Ascending Dose Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01884285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*